Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis-Reference-Cited by-同舟云学术

Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis

Published:2021-04 Issue: Volume:159 Page:105704
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Yao Xueting,Ren Yupeng,Zhao Qian,Chen Xia,Jiang Ji,Liu Dongyang,Hu Pei

Funder

Chinese Academy of Medical Sciences

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference19 articles.

1. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting;Baert;J. Autoimmun.,2018

2. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models;Bergstrand;AAPS J.,2011

3. BAFF, APRIL and their receptors: structure, function and signaling;Bossen;Semin. Immunol.,2006

4. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases;Cheema;Arthritis Rheum.,2001

5. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis;Chen;Clin. Pharmacokinet.,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases;Journal of Autoimmunity;2024-09

2. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis;Frontiers in Immunology;2024-06-06

3. Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod;Frontiers in Immunology;2024-05-10

4. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial;Annals of the Rheumatic Diseases;2023-12-21

5. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy;Clinical Kidney Journal;2023-12